Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib mesylate for advanced hepatocellular carcinoma (prospective, multi-center, single-arm, phase 4)
ChiCTR2100044142Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Nanchang University, Xiangya Hospital of Central South University, Hunan Cancer Hospital
- Start
- Mar 2021
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in hepatocellular carcinoma (HCC), sponsored by The Second Affiliated Hospital of Nanchang University, Xiangya Hospital of Central South University, Hunan Cancer Hospital. Primary endpoints: Progression-free survival, Objective response rate and 4 more. Planned start Mar 2021; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100044142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044142.